The Society for Research into Hydrocephalus and Spina Bifida (SRHSB) was founded in 1956 by a group of physicians and surgeons interested in developing treatments for the conditions. At the time, spina bifida, a spinal condition which develops early in pregnancy resulting in various degrees of paralysis and disability, occurred in over 15 per 10,000 live births, making it one of the most common serious birth defects. In most cases it was accompanied by hydrocephalus – an accumulation of cerebrospinal fluid in the brain which can cause progressive brain damage leading to serious disability and death if left untreated.
NewBridge Pharmaceuticals, headquartered in Dubai, UAE, is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
NewBridge’s current focus is to bring innovation to enhance the patient’s journey in the field of oncology, immunology, neuroscience, gastrointestinal and rare diseases.
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer’s disease.
Add to Calendar
